Login to Your Account

SHANGHAI – Shanghai's Cellular Biomedicine Group Inc. (CBMG) has added a cancer vaccine to its pipeline, a Gvax vaccine it intends to combine with a PD-1 drug in a U.S. phase II study for non-small-cell lung cancer (NSCLC).
HONG KONG – A group of investors, including one from Singapore, have acquired a majority stake in Iceland-based biosimilar and generics maker Alvogen Inc.

Teva Pharmaceutical Industries Ltd. is partnering with drug delivery specialist Microchips Biotech Inc. to develop a tiny implantable chip capable of storing and releasing hundreds of therapeutic doses of drug for periods ranging from months to years. 

More DEALS AND M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: